Germany
· Delayed Price · Currency is EUR Atai Life Sciences Statistics
Total Valuation
ETR:9VC has a market cap or net worth of EUR 436.19 million. The enterprise value is 375.84 million.
| Market Cap | 436.19M |
| Enterprise Value | 375.84M |
Important Dates
The last earnings date was Wednesday, May 14, 2025.
| Earnings Date | May 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 200.34M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +3.07% |
| Shares Change (QoQ) | +9.68% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 111.03M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 253.06 |
| PB Ratio | 3.10 |
| P/TBV Ratio | 3.17 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.73 |
| EV / Sales | 230.72 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -5.16 |
Financial Position
The company has a current ratio of 4.07, with a Debt / Equity ratio of 0.19.
| Current Ratio | 4.07 |
| Quick Ratio | 3.50 |
| Debt / Equity | 0.19 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.37 |
| Interest Coverage | -29.03 |
Financial Efficiency
Return on equity (ROE) is -79.43% and return on invested capital (ROIC) is -28.31%.
| Return on Equity (ROE) | -79.43% |
| Return on Assets (ROA) | -26.04% |
| Return on Invested Capital (ROIC) | -28.31% |
| Return on Capital Employed (ROCE) | -57.90% |
| Revenue Per Employee | 31,919 |
| Profits Per Employee | -2.55M |
| Employee Count | 54 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +41.87% in the last 52 weeks. The beta is 1.23, so ETR:9VC's price volatility has been higher than the market average.
| Beta (5Y) | 1.23 |
| 52-Week Price Change | +41.87% |
| 50-Day Moving Average | 1.40 |
| 200-Day Moving Average | 1.36 |
| Relative Strength Index (RSI) | 71.87 |
| Average Volume (20 Days) | 1,193 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 6.56 |
Income Statement
In the last 12 months, ETR:9VC had revenue of EUR 1.72 million and -137.84 million in losses. Loss per share was -0.84.
| Revenue | 1.72M |
| Gross Profit | 2.09M |
| Operating Income | -89.61M |
| Pretax Income | -138.48M |
| Net Income | -137.84M |
| EBITDA | -89.05M |
| EBIT | -89.61M |
| Loss Per Share | -0.84 |
Balance Sheet
The company has 90.86 million in cash and 26.80 million in debt, giving a net cash position of 64.06 million.
| Cash & Cash Equivalents | 90.86M |
| Total Debt | 26.80M |
| Net Cash | 64.06M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 140.88M |
| Book Value Per Share | 0.70 |
| Working Capital | 80.93M |
Cash Flow
In the last 12 months, operating cash flow was -71.89 million and capital expenditures -947,405, giving a free cash flow of -72.84 million.
| Operating Cash Flow | -71.89M |
| Capital Expenditures | -947,405 |
| Free Cash Flow | -72.84M |
| FCF Per Share | n/a |
Margins
| Gross Margin | 121.04% |
| Operating Margin | -5,198.98% |
| Pretax Margin | -8,034.35% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ETR:9VC does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.07% |
| Shareholder Yield | n/a |
| Earnings Yield | -31.60% |
| FCF Yield | -16.70% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ETR:9VC has an Altman Z-Score of -2.66. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.66 |
| Piotroski F-Score | n/a |